Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of ARA-290 and Thymulin — mechanism, dosing, side effects, legal status, and pricing.
ARA-290 (Cibinetide) is a synthetic 11-amino-acid peptide derived from the helix-B surface of erythropoietin (EPO), developed by Araim Pharmaceuticals. It selectively activates the innate repair receptor (IRR) for anti-inflammatory, tissue-protective, and neuroprotective signaling without stimulating erythropoiesis. ARA-290 is not FDA-approved; it has received FDA Fast Track and Orphan Drug designations for sarcoidosis-associated small fiber neuropathy and remains in clinical development as of April 2026.
Thymulin is a zinc-dependent nonapeptide (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) secreted by thymic epithelial cells, originally isolated by Bach and colleagues in the 1970s as 'facteur thymique sérique' (FTS). It is NOT the same compound as Thymalin (a Russian bovine thymus extract) or Thymosin alpha-1 (a separate 28-amino-acid thymic peptide). Thymulin is not FDA-approved; use is research/investigational only.
ARA-290
Thymulin
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
ARA-290
Thymulin
COA corpus from Disclosed Labs — independently tested batches only.
ARA-290
36
COAs
99.4%
Avg purity
10
Labs
Thymulin
5
COAs
99.5%
Avg purity
4
Labs
Dahan et al. (Molecular Medicine, 2013, PMID 24136731) conducted a blinded placebo-controlled trial of 28 days of subcutaneous ARA 290 in sarcoidosis patients with documented small nerve fiber loss; treatment improved neuropathic symptoms, increased corneal nerve fiber density on confocal microscopy, altered thermal thresholds, and improved 6-minute walk distance. Brines et al. (Molecular Medicine, 2015, PMID 25387363) reported a placebo-controlled trial of 4 mg daily SubQ ARA 290 for 28 days in type 2 diabetes: the active arm showed improvements in HbA1c, lipid profile, and PainDetect neuropathic symptom scores, with recovery of intraepidermal nerve fiber measurements versus no change on placebo. Heij et al. (2012) and additional Phase 2 work have supported the tissue-protective signal. ARA-290 has not advanced to Phase 3 registration trials and is not FDA-approved.
Key references
Bach and Dardenne originally characterized FTS/thymulin and its absolute zinc dependency (Bach & Dardenne, Med Oncol Tumor Pharmacother 1989, PMID 2657247). Prasad et al. (J Clin Invest 1988, PMID 3262625) showed that serum thymulin activity falls in human zinc deficiency and recovers with zinc supplementation. Mocchegiani et al. (Int J Immunopharmacol 1995, PMID 8582782) demonstrated partial reversal of thymic involution with zinc in aged mice. Dardenne & Pleau reviewed zinc-thymulin interactions (Met Based Drugs 1994, PMID 18476235). Safieh-Garabedian et al. (Br J Pharmacol 2002, PMID 12110619) reported analgesic/anti-inflammatory activity of a thymulin-related peptide in rats. There are NO large, modern RCTs of exogenous thymulin in humans; clinical use is experimental.
ARA-290 (Recovery) and Thymulin (Immune) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Dosing Notes
Half-life
Side Effects
Contraindications
Lab Testing
Disclosed Labs